Enterovirus 71 Human
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
2100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
MedigenMD - Frederick
2 programs1
EV71 with adjuvant aluminium phosphatePhase 21 trial
EV71 vaccineN/AVaccine2 trials
Active Trials
Medigen Vaccine BiologicsTaiwan - Taipei
2 programsEV71 vaccineN/AVaccine
EV71 with adjuvant aluminium phosphatePHASE_2
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MedigenEV71 with adjuvant aluminium phosphate
MedigenEV71 vaccine
MedigenEV71 vaccine
Clinical Trials (3)
Total enrollment: 813 patients across 3 trials
A Clinical Study for Inactivated Vaccine Against EV71
Start: Sep 2014Est. completion: Aug 2017366 patients
Phase 2Completed
Long-Term Immunogenicity of Envacgen® in Children
Start: Nov 2025Est. completion: Jul 2026220 patients
N/AActive Not Recruiting
Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children
Start: Aug 2019Est. completion: Dec 2021227 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Vaccine is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.